ALGICON %v/v Oral Suspension

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Toimeaine:

MAGNESIUM ALGINATE ALUMINIUM HYDROXIDE-MAGNESIUM CARBONATE GEL MAGNESIUM CARBONATE POTASSIUM BICARBONATE CALCIUM CARBONATE

Saadav alates:

Rorer Pharmaceuticals Limited

INN (Rahvusvaheline Nimetus):

MAGNESIUM ALGINATE ALUMINIUM HYDROXIDE-MAGNESIUM CARBONATE GEL MAGNESIUM CARBONATE POTASSIUM BICARBONATE CALCIUM CARBONATE

Annus:

%v/v

Ravimvorm:

Oral Suspension

Volitamisolek:

Withdrawn

Loa andmise kuupäev:

2006-04-27

Toote omadused

PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Algicon Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral suspension.
A yellow suspension with the odour and taste of lemon.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
In the treatment of heartburn associated with gastric reflux,
oesophagitis, hiatus hernia, pregnancy and hyperacidity.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
4.3 CONTRAINDICATIONS
None specified. 
w/v
Magnesium alginate
5.00%
Aluminium hydroxide/Magnesium carbonate coprecipitated dry gel
2.80%
Magnesium Carbonate 
3.50%
Potassium Hydrogen Carbonate
1.00%
Precipitated Calcium Carbonate
1.50%
For excipients, see section 6.1
To be taken orally.
Adults:
10 to 20 ml or 1 to 2 sachets four times a day or as directed
by a 
physician.
The suspension should be taken after meals and
at bedtime or as needed.
Children:
Not recommended.
Elderly:
No specific precautions are necessary in normal use.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Issued 10/08/2005_
_CRN 2013441_
_page number: 1_
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION 
Aluminium hydroxide may form complexes with certain drugs e.g.
tetracyclines, digoxin, and vitamins, resulting in 
decreased absorption. This should be borne in mind when
concomitant administration is considered.
4.6 PREGNANCY AND LACTATION
This product should not be used in pregnancy unless considered
essential by the physician.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None.
4.8 UNDESIRABLE EFFECTS
Aluminium hydroxide may cause constipation due to
its astringent action. This effect may be balanced by
the cathartic 
effect of the magnesium salts.
4.9 OVERDOSE
In overdose, abdominal dis